Chen H, Teng L, Li J N, Park R, Mold D E, Gnabre J, Hwu J R, Tseng W N, Huang R C
Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, Beijing, China, Organosilicon and Synthesis Laboratory, Department of Chemistry, National Tsing Hua University, Hsinchu, China-Taiwan.
J Med Chem. 1998 Jul 30;41(16):3001-7. doi: 10.1021/jm980182w.
We had previously reported that tetramethyl-O-NGDA (M4N), a synthetic derivative of the naturally occurring nordihydroguaiaretic acid (NDGA), is able to inhibit HIV Tat transactivation by blocking host Sp1 protein at the Sp1 cognate binding site on the HIV LTR promoter. The present studies were undertaken to examine whether M4N is able to inhibit the replication of herpes simplex virus (HSV), another Sp1-regulated virus. The results showed that in Vero cells, M4N inhibits at micromolar levels (IC50 = 43.5 microM) the expression of the herpes immediate early gene (alpha-ICP4), which is essential for HSV replication. An electrophoretic mobility shift assay, examining Sp1 binding to the alpha-ICP4 promoter, showed a significant inhibition of the control bands: 88% inhibition of the fast moving band (FMB) and 45% of the slow moving band (SMB), at 100 microM of drug concentration. Comparative studies between M4N and acycloguanosine (acyclovir, ACV) in cultured Vero cells revealed an interesting pattern in the drug sensitivity (IC50) and cytotoxicity (TC50) parameters. For M4N, the IC50 varied between 11.7 and 4 microM in 10 passages of HSV-1 and 4 passages of HSV-2 with no indication for a requirement of higher drug concentration. In contrast, for acyclovir, the IC50 increased from 7 microM in the first passage to 444 microM in the tenth passage of HSV-1, and >88 microM for the fourth passage of HSV-2, indicating a rapid build-up of drug resistance against acyclovir. While the selective index (SI), defined as the ratio: TC50/IC50, remained relatively constant for M4N; it dropped 60-fold for acyclovir in the endpoints of viral passages. Drug sensitivity for M4N toward the acyclovir-sensitive strain (sm44) and the acyclovir-resistant strain (ACV-10) of HSV-1 was similar, indicating no cross-resistance between M4N and acyclovir in their anti-HSV effects. These results may have an important clinical relevance since HSV has been shown to be a factor for spreading of HIV.
我们之前曾报道,天然存在的去甲二氢愈创木酸(NDGA)的合成衍生物四甲基 - O - NGDA(M4N)能够通过在HIV长末端重复序列(LTR)启动子上的Sp1同源结合位点阻断宿主Sp1蛋白来抑制HIV Tat反式激活。本研究旨在检测M4N是否能够抑制单纯疱疹病毒(HSV)的复制,HSV是另一种受Sp1调控的病毒。结果显示,在Vero细胞中,M4N以微摩尔水平(IC50 = 43.5 microM)抑制疱疹病毒即刻早期基因(α - ICP4)的表达,该基因对HSV复制至关重要。一项检测Sp1与α - ICP4启动子结合的电泳迁移率变动分析显示,在药物浓度为100 microM时,对照条带受到显著抑制:快速移动条带(FMB)抑制88%,慢速移动条带(SMB)抑制45%。在培养的Vero细胞中对M4N和阿昔洛韦(无环鸟苷,ACV)进行的比较研究揭示了药物敏感性(IC50)和细胞毒性(TC50)参数的有趣模式。对于M4N,在HSV - 1的10次传代和HSV - 2的4次传代中,IC50在11.7至4 microM之间变化,没有迹象表明需要更高的药物浓度。相比之下,对于阿昔洛韦,在HSV - 1的第一次传代中IC50为7 microM,到第十次传代时增加到444 microM,对于HSV - 2的第四次传代,IC50大于88 microM,表明对阿昔洛韦的耐药性迅速增强。虽然定义为TC50/IC50比值的选择性指数(SI)对于M4N保持相对恒定;但在病毒传代终点时,阿昔洛韦的SI下降了60倍。M4N对HSV - 1的阿昔洛韦敏感株(sm44)和阿昔洛韦耐药株(ACV - 10)的药物敏感性相似,表明M4N和阿昔洛韦在抗HSV作用中不存在交叉耐药性。这些结果可能具有重要的临床意义,因为HSV已被证明是HIV传播的一个因素。